» Articles » PMID: 25645920

Novel Roles of C-Met in the Survival of Renal Cancer Cells Through the Regulation of HO-1 and PD-L1 Expression

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2015 Feb 4
PMID 25645920
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

The receptor tyrosine kinase c-Met is overexpressed in renal cancer cells and can play major role in the growth and survival of tumor. We investigated how the c-Met-mediated signaling through binding to its ligand hepatocyte growth factor (HGF) can modulate the apoptosis and immune escape mechanism(s) of renal cancer cells by the regulations of novel molecules heme oxygenase-1 (HO-1) and programmed death-1 ligand 1 (PD-L1). We found that HGF/c-Met-mediated signaling activated the Ras/Raf pathway and down-regulated cancer cell apoptosis; and it was associated with the overexpression of cytoprotective HO-1 and anti-apoptotic Bcl-2/Bcl-xL. c-Met-induced HO-1 overexpression was regulated at the transcriptional level. Next, we observed that c-Met induction markedly up-regulated the expression of the negative co-stimulatory molecule PD-L1, and this can be prevented following treatment of the cells with pharmacological inhibitors of c-Met. Interestingly, HGF/c-Met-mediated signaling could not induce PD-L1 at the optimum level when either Ras or HO-1 was knocked down. To study the functional significance of c-Met-induced PD-L1 expression, we performed a co-culture assay using mouse splenocytes (expressing PD-L1 receptor PD-1) and murine renal cancer cells (RENCA, expressing high PD-L1). We observed that the splenocyte-mediated apoptosis of cancer cells during co-culture was markedly increased in the presence of either c-Met inhibitor or PD-L1 neutralizing antibody. Finally, we found that both c-Met and PD-L1 are significantly up-regulated and co-localized in human renal cancer tissues. Together, our study suggests a novel mechanism(s) by which c-Met can promote increased survival of renal cancer cells through the regulation of HO-1 and PD-L1.

Citing Articles

c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity.

Jabbarzadeh Kaboli P, Roozitalab G, Farghadani R, Eskandarian Z, Zerrouqi A Front Immunol. 2024; 15():1498391.

PMID: 39664377 PMC: 11632105. DOI: 10.3389/fimmu.2024.1498391.


MACC1 revisited - an in-depth review of a master of metastasis.

Schope P, Torke S, Kobelt D, Kortum B, Treese C, Dumbani M Biomark Res. 2024; 12(1):146.

PMID: 39580452 PMC: 11585957. DOI: 10.1186/s40364-024-00689-4.


Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment.

Yao S, Liu X, Feng Y, Li Y, Xiao X, Han Y Int J Mol Sci. 2024; 25(16).

PMID: 39201787 PMC: 11354629. DOI: 10.3390/ijms25169101.


STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.

Saeed A, Tabernero J, Parikh A, Van den Eynde M, Karthaus M, Gerlinger M Future Oncol. 2024; 20(24):1733-1743.

PMID: 39041200 PMC: 11485978. DOI: 10.1080/14796694.2024.2352276.


Immune Response and Metastasis-Links between the Metastasis Driver MACC1 and Cancer Immune Escape Strategies.

Torke S, Walther W, Stein U Cancers (Basel). 2024; 16(7).

PMID: 38611008 PMC: 11010928. DOI: 10.3390/cancers16071330.


References
1.
Datta D, Flaxenburg J, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser A . Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res. 2006; 66(19):9509-18. DOI: 10.1158/0008-5472.CAN-05-4345. View

2.
Kim T, Hur E, Kang S, Kim J, Thapa D, Lee Y . NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res. 2011; 71(6):2260-75. DOI: 10.1158/0008-5472.CAN-10-3007. View

3.
Maina F, Pante G, Helmbacher F, Andres R, Porthin A, Davies A . Coupling Met to specific pathways results in distinct developmental outcomes. Mol Cell. 2001; 7(6):1293-306. DOI: 10.1016/s1097-2765(01)00261-1. View

4.
Thompson R, Kuntz S, Leibovich B, Dong H, Lohse C, Webster W . Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006; 66(7):3381-5. DOI: 10.1158/0008-5472.CAN-05-4303. View

5.
Pilon-Thomas S, Mackay A, Vohra N, Mule J . Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol. 2010; 184(7):3442-9. PMC: 2913584. DOI: 10.4049/jimmunol.0904114. View